EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study

Abhilasha Borad iD, Michael Andersen, Danielle Guffey, Hanqing Shang, Jun Y Jiang, Maria J Fernandez Turizo, Jonathan Berry, Jeffrey I Zwicker, Rushad Patell, Ang Li iD

American Journal of Hematology · 2026-06 · 101 (6) · 1379-1387

DOI: 10.1002/ajh.70287 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 27.03.2026. Verfasst von Abhilasha Borad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Anticoagulants, Venous Thrombosis, Neoplasms. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data to guide management of isolated bland cancer‐associated splanchnic vein thrombosis (CA‐SpVT) are limited. We aimed to assess the role of anticoagulation (AC) and bleeding and thrombosis in patients with CA‐SpVT. We conducted a dual‐center retrospective cohort study of adults with incident, isolated, bland CA‐SpVT from 2011 to 2020. The primary outcome was major bleeding (MB); other outcomes included usual‐site venous thromboembolism (VTE) recurrence and progression/recanalization of CA‐SpVT. Time‐to‐event outcomes were analyzed with weighted Cox models adjusting for cancer type, stage, SpVT location, and whether symptomatic. For SpVT recanalization/progression, differences were estimated using weighted average treatment effects (ATEs). After excluding tumor thrombus, we included 437 patients with notable characteristics of median age 60 years, portal vein thrombosis (81.2%), and underlying hepatocellular cancer (35.9%). Of these, 29.5% received therapeutic AC. At 6 months, there were 11.9% MB and 6.4% incident usual‐site VTE events. Among 308 patients with follow‐up imaging, the 1‐year thrombus progression rate was 19.8% and thrombus recanalization was 28.6%. In the adjusted analysis, there were numerically higher rates of MB with AC (adjusted hazard ratio [aHR] 1.93, 95% confidence interval [CI] 0.97–3.87) and no significant difference in the incidence of VTE (aHR 1.41, 95% CI 0.56–3.51). AC was associated with significantly higher likelihood of venous recanalization (ATE +24% 95% CI 13%–35%) and significantly lower likelihood of thrombus progression (ATE –14% 95% CI –23% to −5%). In patients with isolated bland CA‐SpVT, AC was associated with thrombus recanalization and limited thrombus progression; effects were offset by a potentially higher risk of MB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsVenous ThrombosisNeoplasmsHumansFemaleMiddle AgedMaleRetrospective StudiesAgedHemorrhagePortal VeinCohort StudiesAdultSplanchnic CirculationVenous Thromboembolism

Stichwörter der Autor:innen

anticoagulantshemorrhageneoplasmsportal veinvenous thrombosis

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Hematology-Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Institute for Clinical & Translational Research, Baylor College of Medicine, Houston, Texas, USA.
  • Division of Hematology-Oncology, Keck School of Medicine of University of Southern California, Los Angeles, California, USA.
  • Los Angeles General Medical Center, Los Angeles, California, USA.
  • Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Abhilasha Borad, Ang Li

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS

Zitieren

APA

Borad, A., Andersen, M., Guffey, D., Shang, H., Jiang, J. Y., Fernandez Turizo, M. J., Berry, J., Zwicker, J. I., Patell, R., & Li, A. (2026). The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study. American Journal of Hematology, 101(6), 1379-1387. https://doi.org/10.1002/ajh.70287

Vancouver

Borad A, Andersen M, Guffey D, Shang H, Jiang JY, Fernandez Turizo MJ, et al. The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study. American Journal of Hematology. 2026;101(6):1379-1387. doi:10.1002/ajh.70287

BibTeX
@article{Borad2026,
  author = {Borad, Abhilasha and Andersen, Michael and Guffey, Danielle and Shang, Hanqing and Jiang, Jun Y and Fernandez Turizo, Maria J and Berry, Jonathan and Zwicker, Jeffrey I and Patell, Rushad and Li, Ang},
  title = {The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {6},
  pages = {1379--1387},
  doi = {10.1002/ajh.70287}
}
Kostenlos starten →